en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2007
vol. 45
 
Share:
Send email
Share:
abstract:

Case report
Psoriasis induction during anti-TNF treatment of ankylosing spondylitis

Małgorzata Socik-Pojawa
,
Anna Filipowicz-Sosnowska
,
Małgorzata Przygodzka

Reumatologia 2007; 45, 5: 299-303
Online publish date: 2007/10/31
View full text Get citation
 
Anti-TNF therapy has been found to be a new effective therapeutic option for many autoimmune diseases, such as: rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis and psoriasis. TNF inhibitors reduce the signs and symptoms of an active inflammatory disease and improve the quality of life. Anti-TNF therapy has been approved by the European League Against Rheumatism for the treatment of spondyloarthropathies. Of late, attention has focused on some new data about their skin adverse effects, such as infection, vasculitis, eczema, interstitial granulomatous dermatitis and discoid lupus. Among the most paradoxical skin reactions are the psoriasiform eruptions that have been described during anti-TNF treatment in patients with many autoimmune diseases, excluding psoriasis and psoriatic arthritis. We report a case of psoriasis in a 53-year-old patient with ankylosing spondylitis during etanercept therapy.
keywords:

tumor necrosis factor (TNF), psoriasis, ankylosing spondylitis, etanercept
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.